The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

Grey Matters Health Inc. has received its first brain-dedicated PET scanning system (CareMiBrain) for its flagship NovaScan Neuroimaging Clinic in Davie, Florida, positioning itself as the first U.S. clinic to offer brain-only PET scans for early Alzheimer's detection. The clinic will capitalize on the emerging billion-dollar market created by FDA-approved monoclonal antibody treatments (Leqembi and Kisunla) that require beta-amyloid brain imaging for patient authorization and monitoring.

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth areas like Alzheimer's and rare diseases, with early signs of business stabilization and revenue growth.

A federal court has approved an $18.9 million settlement for investors who purchased Biogen Inc. common stock between June 8, 2021 and July 12, 2021. A settlement hearing is scheduled for September 29, 2026, to determine if the settlement is fair and reasonable. Class members must submit a Proof of Claim by September 24, 2026 to receive compensation.

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement of Phase 2 CELIA study results for diranersen (BIIB080), an Alzheimer's disease treatment. Although Biogen described the results as 'compelling,' the study missed its primary dose-response endpoint, causing the stock to fall $13.16 per share (6.43%) to $191.37 on May 14, 2026.

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

Biogen agreed to acquire private biotechnology company RayThera for up to $1 billion to expand its immunology pipeline. The deal includes an upfront payment with the majority tied to future clinical and regulatory milestones, expected to close in Q3 2026. RayThera focuses on small-molecule therapies for immunological diseases with a lead candidate entering Phase 1 development in early Q3 2026.

Denali Therapeutics announced it will sell its Rare Pediatric Disease Priority Review Voucher for $195 million following FDA approval of AVLAYAH, the first FDA-approved biologic designed to cross the blood-brain barrier. The proceeds will support advancement of Denali's clinical pipeline for lysosomal storage disorders and neurodegenerative diseases. However, the article also notes that Biogen and Denali's Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints, leading to discontinuation of the program.

Biogen has agreed to acquire private biotechnology company RayThera Inc. for up to $1 billion in an upfront payment plus milestone-based contingent payments. The acquisition adds multiple anti-inflammatory assets to Biogen's immunology portfolio, with RayThera's lead candidate expected to enter Phase 1 development in early Q3 2026. The transaction is anticipated to close in Q3 2026.

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement of Phase 2 CELIA study results for diranersen (BIIB080), an Alzheimer's disease treatment. Although Biogen described the results as 'compelling,' the study missed its primary dose-response endpoint, causing the stock to fall $13.16 per share (6.43%) to $191.37 on May 14, 2026.

Biogen's stock fell over 10% after its diranersen Alzheimer's drug missed the primary endpoint in the Phase 2 CELIA trial on May 14. However, the drug showed meaningful reductions in tau pathology and signs of slower clinical decline. Despite the setback, analysts remain bullish with a consensus price target of $215.62, citing the company's decision to advance the drug as a vote of confidence. Biogen's base business is supported by strong Leqembi sales growth (74% YoY to $168M) and the planned Apellis acquisition.

Biogen and Denali Therapeutics announced that BIIB122 (DNL151), a LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The companies will discontinue development in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers. The drug demonstrated acceptable safety and >90% kinase inhibition but did not slow disease progression.